Valeant to acquire Amoun Pharmaceutical for $800 millionStaff writer ▼ | July 18, 2015
Valeant Pharmaceuticals International will acquire Mercury Cayman, the holding company of Amoun Pharmaceutical, for consideration of approximately $800 million, plus contingent payments.
Pharma Mercury holding to be sold
Amoun operates a large, state-of-the-art manufacturing plant that is considered to be one of the largest and most up-to-date pharmaceutical facilities in Africa and the Middle East and has market leading pharmaceutical brands in therapeutic areas such as anti-hypertensives, broad spectrum antibiotics and anti-diarrheals.
Valeant intends for Amoun to serve as a platform for further expansion in the broader Middle East and North Africa pharmaceutical market and expects the transaction to close in the third quarter, subject to customary closing conditions. ■